Evaluation of Urinary Nuclear Matrix Protein as a New Marker for Urinary Bladder Cancer.

Abstract

The purpose of this study was to evaluate urinary nuclear matrix protein 22 (NMP22) as a marker for urinary bladder cancer. Four groups of subjects participated in this study : 18 with a history of bladder cancer without tumors, 12 with urinary bladder tumors, 9 with prostate cancer, and 2 with renal cell cancer. All patients provided a urine sample for urinary NMP22. All bladder cancer patients provided urine cytology before the cystoscopic examination. The mean urinary NMP22 value was 4.6U/ml in bladder cancer patients without tumors, 190.8U/ml in bladder cancer patients with tumors, and 5.8U/ml in patients with other diseases. The NMP22 value in bladder cancer patients with tumors was significantly higher than that in the other groups. The sensitivity and specificity of urinary NMP22 in urinary bladder cancer was 75% and 100%, respectively, and the sensitivity of NMP22 was higher than that of urine cytology. This study indicates that urinary NMP22 is a sensitive, non-invasive marker for detecting urinary bladder cancer.